ravidasvir + danoprevir + ritonavir + ribavirin

A **combination, all-oral direct-acting antiviral regimen of ravidasvir, danoprevir (boosted with ritonavir), and ribavirin** developed primarily for the treatment of **chronic hepatitis C virus (HCV) infection**, genotype 1, in treatment-naïve, non-cirrhotic adult patients. - **Ravidasvir** is a pan-genotypic, second-generation NS5A inhibitor with a high barrier to resistance, interfering with the HCV replication complex[1][3][5]. - **Danoprevir** is a potent macrocyclic NS3/4A serine protease inhibitor, given with low-dose **ritonavir** to boost its bioavailability by inhibiting CYP3A4 metabolism[2][5]. - **Ribavirin** acts as a guanosine analog antiviral, enhancing the efficacy of direct-acting antivirals against HCV. This regimen has demonstrated very high efficacy, with **SVR12 rates (sustained virologic response 12 weeks post-treatment) of 99-100%** in Asian, non-cirrhotic, HCV GT1 patients[1][3][5].

Other names

ravidasvir + ritonavir-boosted danoprevir + ribavirin